Videos

Jason Westin, MD, MS, FACP, discusses the current treatment options for patients with diffuse large B-cell lymphoma that are available besides rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.

Zofia Piotrowska, MD, MHS, discusses the rationale for conducting the FLAURA trial in patients with&nbsp;<em>EGFR</em>-mutant non&ndash;small cell lung cancer and how the use of osimertinib impacted the treatment landscape for this patient population.

Courtney D. DiNardo, MD, MSCE, discusses what is on the horizon for the acute myeloid leukemia setting.

Thomas Powles, MD, MBBS, MRCP, discusses how researchers are working to optimize treatment with immune checkpoint inhibitors for patients with urothelial carcinoma.

Sagar Lonial, MD, FACP, explains the 2 main challenges physicians face when they are treating patients with smoldering multiple myeloma.

David J. Pinato, MD, PhD, discusses the importance of utilizing a multidisciplinary approach when treating patients with hepatocellular carcinoma and how this approach helps optimize patient outcomes now as well as how it will help in the near future as more therapies emerge.

David Miklos, MD, PhD, describes the toxicity profile of KTE-X19, a chimeric antigen receptor T-cell therapy, in the ZUMA-2 trial.

Julie R. Brahmer, MD, discusses the role of molecular testing for patients with lung cancer and why this is particularly important for those with early-stage disease.

Alexey V. Danilov, MD, PhD, discusses important studies in the chronic lymphocytic leukemia space and questions whether combination or sequential therapy is better for patients with chronic lymphocytic leukemia.

A 60-Year Old Man With Untreated Stage IV EGFR-Mutated Non-Small Cell Lung Cancer

Van K. Morris, MD, describes the novel treatments he is excited about in the treatment landscapes for colorectal and anal cancers right now.

Floor J. Backes, MD, discusses the immunotherapeutic options available for treatment of patients with ovarian cancer.

Jorge E. Cortes, MD, explains how ruxolitinib is used to treat various myeloproliferative neoplasms and which patients require other therapies.

Sameer Desai, MD, discusses the changing treatment landscape for lymphomas.

Elizabeth A. Mittendorf, MD, PhD, discusses different data looking at sequencing therapies and why it is important in the breast cancer setting.<br /> &nbsp;

Stephen J. Freedland, MD, discussed&nbsp;an analysis real-world patients with metastatic castration-resistant prostate cancer, which he presented at the 2020 Genitourinary Cancers Symposium.

Dylan Essner explains how Epic, an electronic medical record, can be used by nurses and oncology providers who are treating patients with chimeric antigen receptor T-cell therapy.

A 72-Year-Old Man With Symptomatic Follicular Lymphoma

Lori A. Leslie, MD, discusses chimeric antigen receptor T-cell therapy as a treatment for diffuse large B-cell lymphoma and the positive results demonstrated for this agent in patients with relapsed/refractory disease.